Raphael J. Landovitz, MD

Dr. Landovitz joined the UCLA CARE Center in 2006 after training at Harvard Medical School, Brigham and Women's Hospital, and Massachusetts General Hospital. He also served as medical co-director for the Vietnam CDC Harvard Medical School AIDS Partnership in Ho Chi Minh City, Vietnam. He is an infectious disease and HIV clinician with both a clinical and research interest in HIV and STI prevention, particularly the use of chemoprophylaxis as part of HIV and STI prevention - PrEP, PEP, and microbicides.  He works in the NIH/Division of AIDS-funded ACTG, HPTN and ATN clinical trials networks. He was awarded the John Carey Young Investigator Award by the ACTG in June 2010, and the HIVMAA HIV research award in 2017. He led the NIH-funded clinical trials that supported the 2021 FDA approval of long-acting injectable cabotegravir for HIV PrEP.  Dr. Landovitz lectures and teaches internationally on HIV Prevention, including pre-and post-exposure prophylaxis.